|
|
|
AGREEMENT
This Agreement is made effective as of the 27/th/ day of November, 2002 by and
between CURIS INC., a Delaware corporation, having a place of business at 61
Moulton St., Cambridge, Massachusetts 02138 ("CURIS"), and Ortho Biotech
Products, L.P., a New Jersey limited partnership, having a place of business at
Route 22 East, P.O. Box 6914, Bridgewater, New Jersey, 08807-0914 ("OBI"). CURIS
and OBI are each referred to by name or as a "Party" or, collectively, as
"Parties". References to "CURIS" and "OBI" shall include their respective
Affiliates (hereinafter defined), where appropriate under the terms of this
Agreement.
RECITALS
1. CURIS has on-going research and certain product development and clinical
development capabilities and has identified a lead compound, BMP-7 with the
potential to be further developed for the treatment of renal disease and related
disorders or disorders of the nervous system, from acute or chronic insults.
2. OBI possesses research, development and commercialization capabilities,
as well as proprietary technology in a broad range of therapeutic fields.
3. CURIS desire to license BMP-7 to OBI so that OBI may develop and
commercialize BMP-7 for all indications, except certain orthopedic and dental
indications.
NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto agree as
follows:
ARTICLE I - DEFINITIONS
When used in this Agreement, each of the following terms, when capitalized,
shall have the meaning set forth below. The term shall have the same meaning
whether the singular or plural form is used.
"BMP-7" means BMP-7 protein and nucleic acid and all variants, derivatives,
fragments, antibodies, and agonists thereto and vectors and hosts containing the
foregoing.
"Bone Disease Field" means the prevention or treatment of Osteoporosis,
|
End of Preview |
Home Intelligence Services Subscriptions News About Us